Jia-Li Zhao1,2, Jing Liu3, Ming Fang4, Chen Luo1,2, Zhen-Bang Gu5, Long Huang6,7. 1. Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang, Jiangxi, China. 2. JiangXi Key Laboratory of Clinical and Translational Cancer Research, Nanchang, China. 3. Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. 4. Yangxin People's Hospital of Hubei Province, Huangshi, China. 5. Medical School of Nanchang University, Nanchang, China. 6. Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang, Jiangxi, China. huanglongdoctor@163.com. 7. JiangXi Key Laboratory of Clinical and Translational Cancer Research, Nanchang, China. huanglongdoctor@163.com.
Abstract
BACKGROUND: Meningioma is the most common type of primary intracranial tumor with 0.1-1% of all primary meningiomas have been reported to develop into metastases. However, there is no proven therapeutic strategy for multiple metastases of meningiomas. CASE PRESENTATION: A 60-year-old female accepted total tumor resection of a right frontal lobe meningioma in September 2018, In October 2021, the patient was admitted to hospital because of cough and shortness of breath and diagnosed with metastatic meningiomas. The computed tomography (CT) scan revealed the presence of large masses in the right thoracic and abdominal cavity. After two cycles of anti-PD-1 and anti-VEGF treatment, the symptoms were relieved and the tumor was necrotic. Follow up to June 21, 2022, the patient has been given eleven cycles of the treatment every 3 weeks without tumor progression. CONCLUSIONS: This case showed combined anti-PD-1 and anti-VEGF treatment stimulates peripheral blood immune cells to kill metastatic meningioma cells. Whether combined immunotherapy is more effective for metastatic meningioma needs further exploration.
BACKGROUND: Meningioma is the most common type of primary intracranial tumor with 0.1-1% of all primary meningiomas have been reported to develop into metastases. However, there is no proven therapeutic strategy for multiple metastases of meningiomas. CASE PRESENTATION: A 60-year-old female accepted total tumor resection of a right frontal lobe meningioma in September 2018, In October 2021, the patient was admitted to hospital because of cough and shortness of breath and diagnosed with metastatic meningiomas. The computed tomography (CT) scan revealed the presence of large masses in the right thoracic and abdominal cavity. After two cycles of anti-PD-1 and anti-VEGF treatment, the symptoms were relieved and the tumor was necrotic. Follow up to June 21, 2022, the patient has been given eleven cycles of the treatment every 3 weeks without tumor progression. CONCLUSIONS: This case showed combined anti-PD-1 and anti-VEGF treatment stimulates peripheral blood immune cells to kill metastatic meningioma cells. Whether combined immunotherapy is more effective for metastatic meningioma needs further exploration.
Authors: Kent C Shih; Sajeel Chowdhary; Paul Rosenblatt; Alva B Weir; Gregg C Shepard; Jeffrey T Williams; Mythili Shastry; Howard A Burris; John D Hainsworth Journal: J Neurooncol Date: 2016-06-16 Impact factor: 4.130
Authors: Wenya Linda Bi; Lakshmi Nayak; David M Meredith; Joseph Driver; Ziming Du; Samantha Hoffman; Yvonne Li; Eudocia Quant Lee; Rameen Beroukhim; Mikael Rinne; Ricardo McFaline-Figueroa; Ugonma Chukwueke; Christine McCluskey; Sarah Gaffey; Andrew D Cherniack; Jennifer Stefanik; Lisa Doherty; Christina Taubert; Meghan Cifrino; Deborah LaFrankie; Thomas Graillon; Patrick Y Wen; Keith L Ligon; Ossama Al-Mefty; Raymond Y Huang; Alona Muzikansky; E Antonio Chiocca; Sandro Santagata; Ian F Dunn; David A Reardon Journal: Neuro Oncol Date: 2022-01-05 Impact factor: 12.300
Authors: Simon Bernatz; Daniel Monden; Florian Gessler; Tijana Radic; Elke Hattingen; Christian Senft; Volker Seifert; Michael W Ronellenfitsch; Karl H Plate; Patrick N Harter; Peter Baumgarten Journal: J Mol Histol Date: 2021-02-02 Impact factor: 2.611
Authors: Priscilla K Brastianos; Albert E Kim; Anita Giobbie-Hurder; Eudocia Quant Lee; Nancy Wang; April F Eichler; Ugonma Chukwueke; Deborah A Forst; Isabel C Arrillaga-Romany; Jorg Dietrich; Zachary Corbin; Jennifer Moliterno; Joachim Baehring; Michael White; Kevin W Lou; Juliana Larson; Magali A de Sauvage; Kathryn Evancic; Joana Mora; Naema Nayyar; Jay Loeffler; Kevin Oh; Helen A Shih; William T Curry; Daniel P Cahill; Fred G Barker; Elizabeth R Gerstner; Sandro Santagata Journal: Nat Commun Date: 2022-03-14 Impact factor: 14.919